ZYBRESTAT(TM) (CA4P) Improves Overall Survival In A Phase 2/3 Trial (FACT Study) Of Patients With Anaplastic Thyroid Cancer (ATC)
Median Overall Survival of Patients Receiving ZYBRESTAT Plus Chemotherapy was 5.1 Months, Compared With 4.1 Months for Patients Receiving Chemotherapy Alone
Patients Alive at One-Year More Than Doubled With ZYBRESTAT Plus Chemotherapy Compared With Chemotherapy Alone (23% Vs. 9%)
Almost Half of Patients Treated With ZYBRESTAT Plus Chemotherapy (48%) Were Alive at Six Months, Compared With 37% Treated With Chemotherapy AloneSOUTH SAN FRANCISCO, Calif., Sept. 12, 2010 (GLOBE NEWSWIRE) -- OXiGENE, (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that positive results from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 14th International Thyroid Congress in Paris, France by Rossella Elisei, M.D., of the University of Pisa. In this 80-patient study, the median overall survival (OS) time was 5.1 months for patients who received ZYBRESTAT and chemotherapy when compared with a median survival time of 4.1 months for patients receiving chemotherapy alone (Hazard Ratio 0.71), which represents a 29% reduction in the risk of dying for patients receiving ZYBRESTAT and chemotherapy. Of patients treated with ZYBRESTAT and chemotherapy, 48% were alive at six months, compared with 37% percent of patients treated with the control arm regimen. At one year, 23% of patients treated with ZYBRESTAT and chemotherapy were alive compared to 9% of patients treated with chemotherapy alone. The most common side effects reported with ZYBRESTAT and chemotherapy were neutropenia, transient hypertension and tumor pain. "The results of this study show a clearly demonstrated survival benefit with only transient, manageable side effects," said Michael Tuttle, M.D., Endocrinologist at Memorial Sloan-Kettering Cancer Center who specializes in caring for patients with advanced thyroid cancer. "ZYBRESTAT plus chemotherapy has demonstrated the first significant increase in overall survival without serious side effects in patients with anaplastic thyroid cancer, which should make this an attractive therapeutic intervention for patients for whom there are no other approved effective therapies."
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV